Founded in February 2016, Shanghai glidao pharmaceutical technology co., ltd. is an innovative pharmaceutical research and development company aiming at cutting-edge technologies. Since its establishment, it has successfully carried out three rounds of financing and developed rapidly with the support of investment funds. The company's research and development pipeline focuses on the neurological diseases associated with ion channels, such as pain, epilepsy, depression and neurodegenerative diseases. The company has established close cooperative relationship with domestic and foreign universities, research institutes and listed pharmaceutical groups. Litao has applied for 3 PCT patents, 9 Chinese invention patents, and obtained 2 authorization. The company has recently completed the construction of an ion channel drug research and development platform, which can detect and evaluate all ligand-gated and voltage-gated ion channels, and conduct drug screening and early safety pharmacology studies on ion channel targets.